NCT05226507 - A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Advanced Solid TumorOvarian CancerOvarian Clear Cell CarcinomaOvarian Clear Cell TumorOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Endometrioid TumorARID1A Gene Mutation

Interventions

DRUG

NXP800

NXP800 is an anti-neoplastic, oral small molecule.

Trial Locations (22)

12208

Women's Cancer Care Associates, Albany

19090

Sidney Kimmel Cancer Center, Asplundh Cancer Pavilion, Willow Grove

22908

University of Virginia Health System, Charlottesville

33140

Mount Sinai Comprehensive Cancer Center, Miami Beach

33401

Florida Cancer Specialists Research East, West Palm Beach

33705

Florida Cancer Specialists Research North, St. Petersburg

33901

Florida Cancer Specialists South, Fort Myers

43210

The Ohio State University Comprehensive Cancer Center, Columbus

52242

University of Iowa, Iowa City

73104

OU Health Stephenson Cancer Center, Oklahoma City

74146

Oklahoma Cancer Specialists and Research Institute, Tulsa

76104

Texas Oncology, Fort Worth

77030

The University of Texas MD Anderson Cancer Center, Houston

80045

University of Colorado Cancer Center, Aurora

85016

Honor Health, Phoenix

92093

UC San Diego Health - Moores Cancer Center, La Jolla

97401

Oncology Associates of Oregon, Eugene

06511

Yale Gynecologic Oncology, New Haven

08901

Rutgers Cancer Institute of New Jersey, New Brunswick

SM2 5PT

Royal Marsden Hospital, Sutton

CB2 0QQ

Addenbrookes Hospital, Cambridge

G12 0YN

The Beatson West of Scotland Cancer Centre, Glasgow